The aim of this study was to assess the influence of atrial natriuretic factor (ANF) on arterial baroreflex chronotropic responses and to investigate whether this effect of ANF is affected by angiotensin converting enzyme inhibition (CEI). For this purpose, in 13 normal volunteers, the reflex chronotropic responses to arterial baroreceptor stimulation (phenylephrine, 25-100 jig i.v.) or deactivation (nitroglycerin, 25-100 ,g i.v.) were evaluated in control conditions and during the steady-state phase of a sustained infusion of ANF (50 ng/kg/min) or placebo, before and during prolonged treatment with the converting enzyme inhibitor enalapril (20 mg p.o. for 5 days). ANF infusion, which raised plasma ANF levels from 48±19 to 1,765±203 pg/ml, was associated with a slight decrease in systemic blood pressure and no change in heart rate. In addition, it caused a significant increase of the regression slope obtained with phenylephrine (from 11.3+±2 to 18.5+±2 msec/mm Hg) and a significant reduction of slope of the nitroglycerinproduced regression line (from 9.3+±1 to 5.6±0.6 msec/mm Hg). After sustained CEI, which raised plasma renin activity from 1.4+±0.4 to 19.9±5 ng/ml/hr, ANF infusion induced an increase in plasma ANF levels and a reduction in blood pressure comparable to those observed in control conditions. During CEI, however, ANF infusion had no significant effect on the chronotropic baroreflex responses produced by phenylephrine or nitroglycerin. Chronotropic and pressor responses to cold exposure were unchanged after CEI 
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Methods

Subjects and General Procedures
The study was performed in 13 normal volunteers of both sexes whose ages ranged from 22 to 38 years (body weight, 66.5-72.5 kg). Informed, written consent was obtained from each subject before the study. The protocol was approved by the Research Committee of our institution. In the week preceding the first experimental session and throughout the study, the subjects were maintained on a standard daily diet containing 1,500 ml fluids, 130 meq sodium, and 60 meq potassium. Two days before the study, the subjects were made familiar with the experimental procedure, and the day preceding the study they were required to abstain from caffeine, alcohol, smoking, and strenuous exercise. The studies were always performed in the morning, starting between 10:30 and 11:30 AM after an overnight fast, with the subject in the supine position, in a quiet room with the temperature kept constant between 220 and 240 C.
Instrumentation
Pulsatile arterial blood pressure was measured by a short heparinized polyethylene cannula introduced percutaneously into the brachial artery (after local anesthesia with 2% procaine solution) and connected to a pressure transducer. The R-R interval was measured by monitoring lead II of an electrocardiogram at high speed (50 mm/sec) recording. A thin polyethylene catheter was introduced percutaneously into an antecubital vein for drug or fluid administration, while another heparinized polyethylene 5F catheter introduced through a contralateral antecubital vein was advanced to the right atrium. Intraarterial blood pressure, right atrial pressure, and heart rate were monitored continuously. Systemic and atrial pressures were measured through Statham P23db pressure transducers connected to a multichannel polygraph.
Blood samples for measurement of plasma levels of immunoreactive ANF (irANF) and plasma renin activity (PRA) were obtained from the arterial line. The samples were collected in chilled tubes, rapidly spinned in a cold centrifuge, and stored at -40°C.
Techniques for Studying Arterial Barorefiexes
The technique used to evaluate the arterial baroreflexes, which was suited for evaluating baroreceptor control of heart rate, was based on the chronotropic response to the pharmacological manipulation of blood pressure. Phenylephrine bolus injection (25-100 ,g i.v.) was used to increase blood pressure by at least 20 mm Hg and nitroglycerin (25-150 ,ug i.v.) to lower it by at least 20 mm Hg. The drugs were injected during a period of 5-10 seconds in order to cause blood pressure and reflex heart rate changes that reached a maximum and were then sustained for 5-10 seconds. To analyze the effects of vasoactive drugs, we calculated the average systolic arterial and heart interval during the 10-second period before injection and during the ramp of the pressure changes. The responses were evaluated by calculating the slope of the regression lines obtained by plotting each R-R interval against the corresponding preceding value of systolic blood pressure, according to the method described by Smyth et al. 32 To provide a more detailed analysis of the baroreflex responses, the gain of the baroreceptor reflex control of heart rate was also determined by the ratio of the percent change in R-R interval to the corresponding change in systolic arterial pressure.
Protocol
Thirty minutes after placement of intravascular catheters, hemodynamic (blood pressure, heart rate, and right atrial pressure) and hormonal (immunoreactive ANF, plasma renin activity) baseline measurements were obtained. Subsequently, repeated bolus (three to five) injections of phenylephrine and nitroglycerin were made in a random order, with each injection separated from the preceding one by at least 10 minutes. Injections of vehicle alone were also interposed and did not elicit any hemodynamic effect. The subjects were asked to breathe regularly and were unaware of the site of injections. To evaluate the vascular and chronotropic response to direct stimulation of sympathetic nervous system, after recovery a cold pressor test was performed. Exposure to cold was obtained by immersing one hand of the subject in water at 40 C for 90 seconds.
After recovery, measurements were repeated again to obtain a new baseline. A constant infusion of ANF (a-human-1-28 atrial natriuretic peptide, Bissendorf peptide GMBh, FRG) (50 ng/kg/min) was then started. After 15 minutes of infusion, that is, when the increase in plasma levels achieved equilibrium, hemodynamic and hormonal measurements were performed to evaluate the direct effects of the peptide. Finally, arterial baroreflexes were assessed again as described above, whereas the ANF infusion was continued.
On the day after the first experimental session, eight subjects started a treatment with the angiotensin converting enzyme inhibitor, enalapril (Enapren, Merck To examine the influence of venous pressure on the baroreflex responses, in four separate normal subjects (two men, two women; mean age 29+4 years) we studied the reflex responses to phenylephrine and nitroglycerin in the supine position and after the subjects had been sitting for 15 minutes, before and during ANF infusion (50 ng/kg/min for 15 minutes). In these subjects, central venous pressure, systemic blood pressure, and heart rate were measured.
Hornonal Assays PRA was measured by radioimmunoassay (sensitivity: 50 pg/tube angiotensin I; intra-assay and interassay variability coefficients, 5.8% and 9.7%, respectively).
Plasma immunoreactive ANF levels were determined by radioimmunoassay using rabbit antiserum (Peninsula), iodinated human ANF-(99-126) (2, 200 Ci/mmol, Amersham), and human ANF-(99-126) (Nova Biochem) as a standard. ANF was extracted from plasma with Sep-Pak C18 cartridges (Waters Associates, Milford, Mass.). The recoveries determined on each plasma sample ranged from 72% to 86%. The eluates were dried overnight in a Savant speed-vac evaporator and reconstituted in radioimmunoassay buffer. The assay was performed in disequilibrium conditions. Intra-assay and interassay variation coefficients were 6.2% and 10.1%, respectively. The radioimmunoassay sensitivity was 2.0 pg/tube.
Data Analysis
The data obtained by injection of vasoactive drugs calculated during the ramp phase of the pressure changes were analyzed by linear regression analysis. The average slope obtained in each subject was used for further analysis. Significant linear regression coefficients were always found between systolic blood pressure and the subsequent R-R interval (r was never less than 0.70, p was never greater than 0.01).
Student's t test for paired data was used for comparisons of data with normal distribution within the same subjects. Wilcoxon's nonparametric test was applied for the analysis of data with nonnormal distribution. Two-way analysis of variance was used for comparisons of the reflex gain. All data are reported as mean±SEM. To analyze the baroreflex responses, regression lines were obtained relating the drug-induced changes in systolic blood pressure and the R-R interval. As shown in Figure 2, The average regression slope obtained by reducing systolic blood pressure by nitroglycerin showed a slight, but significant, reduction after ANF infusion (from -9.3± 1 to -5.6±0.6 msec/mm Hg, p<0.05) (Figure 1) . Inspection of the reflex gain confirmed that ANF administration tended to depress the reflex tachycardia for each level of nitroglycerin-induced hypotension (Figure 3, upper panel) .
After chronic converting enzyme inhibition with enalapril, the baseline reflex chronotropic response to phenylephrine was not different from that observed before enalapril (Figure 1 ). In contrast, the average regression slope of the response to nitroglycerin was significantly reduced (-5.9±0.5, p<0.05 vs. pretreatment baseline value) (Figure 1) .
ANF infusion during converting enzyme inhibition was unable to modify both chronotropic baroreflex responses. In particular, after enalapril, ANF did not enhance the bradycardic response to phenylephrine (Figures 1 and 2 , lower panel) and did not blunt the reflex response to nitroglycerin (Figures 1 and 3 , lower panel) as observed in control conditions.
To evaluate the possible influence of venous pressure, the effects of ANF on baroreflex responses were studied also in the supine and sitting positions. As shown in Table 2 , ANF enhanced the bradycardic response to phenylephrine and attenuated the tachycardic response to nitroglycerin independently of central venous pressure level.
Cold Pressor Test
Cold exposure caused significant increases in mean blood pressure and in heart rate that were similar before and during converting enzyme inhibition and were unaltered during the steady state of ANF infusion in both conditions ( Figure 5 ).
The reproducibility of the reflex responses evoked by both the vasoactive drugs was assessed in a separate group of five subjects, both within the same session and in two different sessions separated by 5 days of placebo administration. The intrastudy variability for the regression slope obtained with phen- (CPT) at normal and elevated levels of atrial natriuretic factor (ANF) before and during converting enzyme inhibition (CEI). Both mean arterial pressure (MAP) and heart rate (HR) were increased significantly (p<O.OS) by CPT in all conditions. DAM CPT ylephrine and nitroglycerin was 12.2% and 13.4%, respectively. The interstudy variability for the two regression slopes was 14.5% for phenylephrine and 15.3% for nitroglycerin. Discussion In the present study, the interactions of ANF with the baroreflex control of heart rate were examined in humans under control conditions and after converting enzyme inhibition.
Our major findings were 1) baroreflex-mediated bradycardia in response to phenylephrine administration is enhanced during ANF infusion, but this effect is abolished by converting enzyme inhibition, 2) baroreflex-mediated tachycardia caused by nitroglycerin injection is attenuated by ANF Similarly, it appears unlikely that the influence of sustained converting enzyme inhibition on baroreceptor responses was mediated by an interaction with the sympathetic nervous system. In fact, the hemodynamic response to cold was comparable before and during enalapril. Finally, the observation that ANF did not affect the blood pressure responses to vasoactive agents or the sympathetically mediated reflex response to cold minimizes the possibility that the effects of ANF on baroreceptor responses are mediated by peripheral vascular effects or interactions with the direct sympathetic responses.
In conclusion, it seems reasonable to speculate that the influence of ANF on reflex chronotropic responses to baroreceptor manipulation might be related to functional antagonism of Ang II actions on baroreflex pathways. Our experiments cannot clarify at which level ANF may antagonize the effects of Ang II. The observation that the distribution of ANF-containing neurons and receptors in the central nervous system overlap with that observed for Ang 116,7 and that intracerebroventricular administration of ANF antagonizes the biological effects of Ang II25 may suggest an interaction of the two peptides at the central nervous system level.
